Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda

PLoS Medicine

Volumn 13, Issue 8, 2016, Pages

  Baeten, Jared M ^a   Heffron, Renee ^a   Kidoguchi, Lara ^a   Mugo, Nelly R ^a,b   Katabira, Elly ^c   Bukusi, Elizabeth A ^a,b   Asiimwe, Stephen ^d   Haberer, Jessica E ^e   Morton, Jennifer ^a   Ngure, Kenneth ^f   Bulya, Nulu ^c   Odoyo, Josephine ^b   Tindimwebwa, Edna ^d   Hendrix, Craig ^g   Marzinke, Mark A ^g   Ware, Norma C ^h   Wyatt, Monique A ^h,i   Morrison, Susan ^a   Haugen, Harald ^a   Mujugira, Andrew ^a   Donnell, Deborah ^a,j   Celum, Connie ^a   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c MAKERERE UNIVERSITY   (Uganda)

^d Kabwohe Clinical Research Center   (Uganda)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Kenya)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ Harvard Global Health Institute   (United States)

^j Fred Hutchinson Cancer Research Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRE-EXPOSURE PROPHYLAXIS; PROSPECTIVE STUDY; SEXUAL TRANSMISSION; UGANDA; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; INTEGRATED HEALTH CARE SYSTEM; MEDICATION COMPLIANCE; ORGANIZATION AND MANAGEMENT; PROCEDURES; SEXUALITY; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTI-HIV AGENTS; DELIVERY OF HEALTH CARE, INTEGRATED; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; KENYA; MALE; MEDICATION ADHERENCE; PRE-EXPOSURE PROPHYLAXIS; PROSPECTIVE STUDIES; SEXUAL PARTNERS; UGANDA; YOUNG ADULT;

EID: 84988980974     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002099     Document Type: Article

References (22)

1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365: 493–505. doi: 10.1056/ NEJMoa1105243 PMID: 21767103
2. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367: 399–410. doi: 10.1056/ NEJMoa1108524 PMID: 22784037
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363: 2587–2599. doi: 10. 1056/NEJMoa1011205 PMID: 21091279
4. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014; 14: 820–829. doi: 10.1016/S1473-3099(14)70847-3 PMID: 25065857
5. Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014; 66: 340–348. doi: 10.1097/QAI.0000000000000172 PMID: 24784763
6. Dunkle KL, Stephenson R, Karita E, Chomba E, Kayitenkore K, Vwalika C, et al. New heterosexually transmitted HIV infections in married or cohabitating couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet. 2008; 371: 2183–2191. doi: 10.1016/S0140-6736(08)60953-8 PMID: 18586173
7. World Health Organization (2012) Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendation for use in the context of demonstration projects. Geneva: World Health Organization.
8. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin I, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011; 8: e1001123. doi: 10.1371/journal.pmed.1001123 PMID: 22110407
9. Ying R, Sharma M, Heffron R, Celum CL, Baeten JM, Katabira E, et al. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. J Int AIDS Soc. 2015; 18: 20013. 20010.27448/IAS.20018.20014.20013. eCollection 22015. doi: 10.7448/IAS.18.4.20013 PMID: 26198348
10. Mujugira A, Celum C, Thomas KK, Farquhar C, Mugo N, Katabira E, et al. Delay of antiretroviral therapy initiation is common in East African HIV-infected individuals in serodiscordant partnerships. J Acquir Immune Defic Syndr. 2014; 66: 436–442. 410.1097/QAI.0000000000000192. doi: 10.1097/QAI. 0000000000000192 PMID: 24798765
11. Kahle EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba E, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr. 2013; 62: 339–347. doi: 10.1097/QAI.0b013e31827e622d PMID: 23187945
12. Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013; 10: e1001511. doi: 10.1371/journal.pmed.1001511 PMID: 24058300
13. Anglemyer A, Rutherford GW, Horvath T, Baggaley RC, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 2013; 4: CD009153. doi: 10.1002/14651858.CD009153.pub3 PMID: 23633367
14. Batani J, Brum T, Calvet G, Dusara P, Dhayarkar S, Gamble T, et al. Acceptance of ART in the delay drm after notification of interim study results: Data from HPTN 052. Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections; March 4, 2013; Atlanta, GA.
15. Ngure K, Curran K, Vusha S, Ngutu M, Mugo N, Celum C, et al. Following the doctor's advice: experiences of HIV serodiscordant couples enrolled in a PrEP demonstration Project in Kenya. Paper presented at: HIV Research for Prevention (R4P); October 28–31, 2014; Cape Town, South Africa. Abstract P46.06.
16. Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012; 54: 1504– 1513. doi: 10.1093/cid/cis225 PMID: 22474224
17. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372: 509–518. doi: 10. 1056/NEJMoa1402269 PMID: 25651245
18. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367: 411–422. doi: 10.1056/ NEJMoa1202614 PMID: 22784040
19. Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014; 59 Suppl 1: S55–60. doi: 10.1093/cid/ciu266 PMID: 24926036
20. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015; 9: 00056–00052.
21. World Health Organization (2015) Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO. 78 p.
22. Kenya Ministry of Health. Kenya HIV prevention revolution road map: Count down to 2030. http://www. nacc.or.ke/images/documents/Final.pdf.